[go: up one dir, main page]

HRP20040758B1 - Uporaba il-18 inhibitora za lijeäśenje i/ili prevenciju perifernih krvožilnih bolesti - Google Patents

Uporaba il-18 inhibitora za lijeäśenje i/ili prevenciju perifernih krvožilnih bolesti

Info

Publication number
HRP20040758B1
HRP20040758B1 HRP20040758AA HRP20040758A HRP20040758B1 HR P20040758 B1 HRP20040758 B1 HR P20040758B1 HR P20040758A A HRP20040758A A HR P20040758AA HR P20040758 A HRP20040758 A HR P20040758A HR P20040758 B1 HRP20040758 B1 HR P20040758B1
Authority
HR
Croatia
Prior art keywords
prevention
treatment
peripheral vascular
inhibitors
vascular diseases
Prior art date
Application number
HRP20040758AA
Other languages
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Merck Serono Sa filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of HRP20040758A2 publication Critical patent/HRP20040758A2/hr
Publication of HRP20040758B1 publication Critical patent/HRP20040758B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Izum se odnosi na uporabu inhibitora IL-18 za pripremu lijeka za tretman i/ili prevenciju bolesti perifernih žila. Izum nadalje se odnosi na uporabu inhibitora IL-18 za prevenciju amputacije ekstremiteta.
HRP20040758AA 2002-03-22 2004-08-23 Uporaba il-18 inhibitora za lijeäśenje i/ili prevenciju perifernih krvožilnih bolesti HRP20040758B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100290 2002-03-22
PCT/EP2003/050061 WO2003080104A2 (en) 2002-03-22 2003-03-13 Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases

Publications (2)

Publication Number Publication Date
HRP20040758A2 HRP20040758A2 (en) 2005-02-28
HRP20040758B1 true HRP20040758B1 (hr) 2012-10-31

Family

ID=28051827

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040758AA HRP20040758B1 (hr) 2002-03-22 2004-08-23 Uporaba il-18 inhibitora za lijeäśenje i/ili prevenciju perifernih krvožilnih bolesti

Country Status (28)

Country Link
US (2) US9592267B2 (hr)
EP (1) EP1487541B1 (hr)
JP (1) JP4885424B2 (hr)
KR (1) KR20050004809A (hr)
CN (1) CN100540058C (hr)
AR (1) AR039103A1 (hr)
AT (1) ATE414556T1 (hr)
AU (1) AU2003219162B2 (hr)
BR (1) BRPI0308663B8 (hr)
CA (1) CA2478855C (hr)
CY (1) CY1108748T1 (hr)
DE (1) DE60324777D1 (hr)
DK (1) DK1487541T3 (hr)
EA (1) EA008495B1 (hr)
ES (1) ES2314191T3 (hr)
HK (1) HK1075422A1 (hr)
HR (1) HRP20040758B1 (hr)
IL (2) IL164211A0 (hr)
ME (1) ME00548B (hr)
MX (1) MXPA04009135A (hr)
NO (1) NO336226B1 (hr)
PL (1) PL207303B1 (hr)
PT (1) PT1487541E (hr)
RS (1) RS51755B (hr)
SI (1) SI1487541T1 (hr)
UA (1) UA80275C2 (hr)
WO (1) WO2003080104A2 (hr)
ZA (1) ZA200407022B (hr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
UA80275C2 (en) 2002-03-22 2007-09-10 Applied Research Systems Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases (variants)
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2005102282A1 (en) * 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
ES2370417T3 (es) 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
PL1891088T3 (pl) 2005-06-10 2012-03-30 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151240A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
AU2010292486B2 (en) 2009-08-27 2014-08-07 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
WO2011041584A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2012025536A1 (en) 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
ES2811515T3 (es) 2010-12-29 2021-03-12 Strategic Science & Tech Llc Tratamiento de disfunción eréctil y otras indicaciones
CN105878172A (zh) 2010-12-29 2016-08-24 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
AU2016227644B2 (en) 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009063A1 (en) * 1997-08-14 1999-02-25 Yeda Research And Development Co. Ltd. Interleukin-18 binding proteins, their preparation and use
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
EP0974600A2 (en) * 1998-06-24 2000-01-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Anti-interleukin-18 antibody
EP1101772A1 (en) * 1999-11-16 2001-05-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
EP1110969A1 (en) * 1998-09-01 2001-06-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
WO2001085201A2 (en) * 2000-05-05 2001-11-15 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2001090063A2 (en) * 2000-05-19 2001-11-29 Vertex Pharmaceuticals Incorporated Prodrug of an ice inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
UA80275C2 (en) 2002-03-22 2007-09-10 Applied Research Systems Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases (variants)

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
WO1999009063A1 (en) * 1997-08-14 1999-02-25 Yeda Research And Development Co. Ltd. Interleukin-18 binding proteins, their preparation and use
EP0974600A2 (en) * 1998-06-24 2000-01-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Anti-interleukin-18 antibody
EP1110969A1 (en) * 1998-09-01 2001-06-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1101772A1 (en) * 1999-11-16 2001-05-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
WO2001085201A2 (en) * 2000-05-05 2001-11-15 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2001090063A2 (en) * 2000-05-19 2001-11-29 Vertex Pharmaceuticals Incorporated Prodrug of an ice inhibitor

Also Published As

Publication number Publication date
JP2005520852A (ja) 2005-07-14
US9592267B2 (en) 2017-03-14
BR0308663A (pt) 2005-01-25
HK1075422A1 (en) 2005-12-16
WO2003080104A2 (en) 2003-10-02
US20060233799A1 (en) 2006-10-19
MXPA04009135A (es) 2004-12-07
CA2478855A1 (en) 2003-10-02
US20100291028A1 (en) 2010-11-18
AR039103A1 (es) 2005-02-09
JP4885424B2 (ja) 2012-02-29
DK1487541T3 (da) 2009-01-19
EA200401240A1 (ru) 2005-02-24
RS51755B (en) 2011-12-31
DE60324777D1 (de) 2009-01-02
US9566313B2 (en) 2017-02-14
EP1487541A2 (en) 2004-12-22
KR20050004809A (ko) 2005-01-12
PL207303B1 (pl) 2010-11-30
ME00548B (me) 2011-10-10
EP1487541B1 (en) 2008-11-19
ES2314191T3 (es) 2009-03-16
CA2478855C (en) 2013-12-17
PT1487541E (pt) 2008-12-10
PL372398A1 (en) 2005-07-25
ATE414556T1 (de) 2008-12-15
CY1108748T1 (el) 2014-04-09
AU2003219162B2 (en) 2008-01-03
HRP20040758A2 (en) 2005-02-28
NO336226B1 (no) 2015-06-22
RS81504A (en) 2006-12-15
AU2003219162A1 (en) 2003-10-08
WO2003080104A3 (en) 2004-03-04
BRPI0308663B8 (pt) 2021-05-25
BRPI0308663B1 (pt) 2019-07-16
ZA200407022B (en) 2006-06-28
CN1655845A (zh) 2005-08-17
EA008495B1 (ru) 2007-06-29
SI1487541T1 (sl) 2009-02-28
UA80275C2 (en) 2007-09-10
IL164211A0 (en) 2005-12-18
NO20044459L (no) 2004-10-20
CN100540058C (zh) 2009-09-16
IL164211A (en) 2011-07-31

Similar Documents

Publication Publication Date Title
HRP20040758B1 (hr) Uporaba il-18 inhibitora za lijeäśenje i/ili prevenciju perifernih krvožilnih bolesti
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
ECSP045429A (es) Combinacion de compuestos organicos
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
ATE323490T1 (de) Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
SE0200667D0 (sv) Novel use of cytokine inhibitors
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
ATE534380T1 (de) Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
MXPA05010416A (es) Combinacion de substancias activas de aceites minerales que contienen acidos grasos (3 con extractos vegetales que contengan polifenoles y su uso.
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
DE60330233D1 (de) Arsentherapie zur behandlung von autoimmunerkrankungen
TNSN05154A1 (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
BRPI0416755A (pt) uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa
ECSP993018A (es) Nuevos inhibidores de proteasas, particularmente inhibidores de cisteina y serina proteasas

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: MERCK SERONO SA, CH

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190207

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200205

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210312

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220309

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20230313